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SUSTAINED EFFICACY OF INTRA-ARTICULAR FX006 IN A RAT MODEL OF
OSTEOARTHRITIS
A. Kumar 1, A.M. Bendele 2, R.C. Blanks 1, N. Bodick 1. 1 Flexion Therapeutics,
Woburn, MA, USA; 2Bolder BioPATH, Boulder, CO, USA
Purpose: To develop a localized rat knee streptococcal peptidoglycan-
polysaccharide (PGPS) model of osteoarthritis and to evaluate the efﬁcacy
of single intra-articular (IA) doses of FX006, a sustained release formula-
tion of triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid)
(PLGA) microspheres and Kenalog-40, a crystalline suspension of TCA.
Methods: The PGPS model was modiﬁed to induce localized knee osteo-
arthritis with synovitis and assess prolonged duration of efﬁcacy. Synovitis
was induced in the right knees of 75 rats with injection of PGPS twoweeks
prior to treatment with a single IA injection of FX006 on Day 1 (TCA in
PLGA microspheres), Kenalog, or vehicle. Three ﬂares of synovitis were
induced with tail vein injections of PGPS on Days 1 (2.5 hours after IA
dosing), and subsequently on Days 14 and 28 (with no further dosing with
treatments). FX006 was administered at doses of 0.28, 0.12 or 0.03 mg TCA
and Kenalog at 0.06 mg (which provides overall TCA exposure compa-
rable to FX006 at 0.28 mg; AUCw 350 ng.hr/mL). Differences in weight-
bearing and gait (as a measure of knee pain), histopathology, pharmaco-
dynamics (serum corticosterone) and plasma pharmacokinetics (PK) were
characterized.
Results: As shown in the Figure, upon each reactivation of synovitis,
vehicle-treated animals demonstrated a period of impaired gait (Note:
higher scores indicate greater impairment). Animals injected with a single
IA dose of 0.28 mg FX006 on Day 1 demonstrated signiﬁcant improvement
in gait scores through all three reactivations induced on Days 1, 14, and 28.
Animals injected with 0.06 mg of Kenalog on Day 1 demonstrated
signiﬁcant improvement in gait scores through the 1st reactivation, dimi-
nution of effect in the 2nd reactivation and absence of effect in the 3rd
reactivation. FX006 demonstrated dose-dependence in the magnitude and
duration of effect (data not shown). Though the total amount of TCA in the
high dose of FX006 is approximately 5X the amount in the Kenalog
injection, the Cmax at this dose was 1/10th, and systemic exposure
comparable to that provided by the Kenalog injection (the Cmax in
Kenalog-treated animals of 17 ng/mL was also greater than that reported
following the labeled 40 mg IA dose in patients). Histopathological eval-
uation of the knees taken at the end of the study demonstrated dose
dependent, statistically signiﬁcant improvement by FX006 in the
composite histological score and each component score (inﬂammation,
pannus, cartilage damage and bone resorption) with scores approximating
normal tissue architecture at the high and mid-dose of FX006. All treat-
ment groups had similar corticosterone levels at baseline that were
initially inhibited following both Kenalog and FX006 treatment, but
recovered by Day 14.
ĂConclusions: In a modiﬁed PGPS model of localized knee osteoarthritis in
rats, the prolonged release of TCA from PLGA microspheres following
a single IA injection of FX006 resulted in extended duration of efﬁcacy and
a signiﬁcant improvement in histological scores of joint tissues compared
to Kenalog administered at a dose providing comparable exposure.FX006 produced these effects with low systemic exposure and without
prolonged inhibition of the HPA axis.
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COMPLIANCE WITH THROMBOPROPHYLAXIS USING AN ORAL FACTOR
XA INHIBITOR RIVAROXABAN AFTER TOTAL HIP AND KNEE
ARTHROPLASTY. IS ORAL THERAPY BETTER? AN EXAMINATION OF
THE NON-ADHERENCE RATE OF RIVAROXABAN
S. Rodriguez-Elizalde 1,2, J. Murnaghan 2,1, D. Murnaghan 2, H. Razmjou 2,
J. Gollish 2. 1 Sunnybrook Hlth.Sci. Ctr., Toronto, ON, Canada; 2Univ. of
Toronto, Toronto, ON, Canada
Introduction: Post-operative thrombo-prophylaxis is believed to reduce
the perioperative risk for patients following total hip and knee arthro-
plasty. The non-adherence rate in the literature for patients completing
their prescribed course of traditional thrombo-prophylaxis varies from 5-
40%. Newer oral thrombo-prophylatic agents are now available (factor Xa
inhibitors), however their patient compliance rate is unknown. This study
compares the compliance rate of a prescribed oral factor Xa inhibitor,
Rivaroxaban, for the thrombo-prophylaxis of post-operative hip and
knee arthroplasty patients and compares it to the established literature
compliance rates of other modalities. The non-adherent patients were
then subgroup analysed to examine for non-compliant patient risk factors.
Methods: Since January 2010, an on going prospective database for all total
joint replacement surgeries has followed patients treated with thrombo-
prophylaxis post-operatively. As a standard of care, a self-administered
questionnaire is recorded at the six-week mark. This includes information
about the medication used for thrombo-prophylaxis, the prescription
administration, compliance and complications from therapy. The compli-
ance of their prescribed fourteen-day therapy was then calculated and
compared to the published literature compliance rates of other thrombo-
prophylaxis agents. A sub-group analysis was then undertaken of the non-
adherence (NA) group.
Results: A total of 1789 patients (1343 total knees and 947 total hips)
received a prescription for Rivaroxaban post-operatively. Of these, 53
(3.0%) did not complete their six-week follow up questionnaire. Another
52 (2.9%) stated they did not complete the entire course of prescribed
therapy. The overall compliance rate of those given a prescription is 97.1%.
If we assume all those lost to follow-up did not complete their prescribed
course, the compliance drops to 94.1%, leaving a non-adherence (NA) rate
of 5.9% for Rivaroxaban.
The group of stated non-adherent patients were more likely to be female
(71.2% vs 60.1%, p¼0.03), and were trending to have a higher BMI (30.6 vs
28.9, p¼0.08). Age was not a factor for either group. Four patients who
were NA encountered bleeding complications, compared to 18 in the
compliant group (7.5% vs 1.1% p¼0.01).
Discussion: This study demonstrates that patients are more likely to
complete a thrombo-prophylaxis regime on an oral Factor Xa inhibitor
than other therapies. The stated NA rate of prescribed Rivaroxaban is 2.9%.
Assuming all those lost to follow-up were non-adherent, the calculated
overall NA rate would be 5.9%. This compares favourably to the non-
adherence rates of injectable low molecular weight, which has multiple
published series demonstrating NA of 5-40%, and most recently, a large
multi-center series of 1315 patients showing a NA of 20.8%. This study
demonstrates that the prescription of rivaroxaban affords a superior
patient compliance compared with subcutaneous LMWH.
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MCP-1 AND RANTES LEVELS IN THE SINOVIUM OF OSTEOARTHRITIC
PATIENTS ARE REDUCED AFTER TREATEMENT WITH CHONDROITIN
SULFATE BUT NOT WITH PARACETAMOL
P. Escudero 1,2, L. Tío 3, L. Piqueras 1, C. Company 1,2, M. Sanz 1,2,
J. Monfort 4. 1Dept. of Pharmacology Univ. of Valencia, Valencia, Spain;
2Univ.ry Clinic Hosp. Res. Fndn.-INCLIVA, Univ. of Valencia, Valencia, Spain;
3 FIMIM, Barcelona, Spain; 4 Parc de Salut Mar, Barcelona, Spain
Purpose: The aim of this study was to investigate the clinical conse-
quences and the levels of chemokines in OA patients treated either with
chondroitin sulphate (CS) or paracetamol.
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S290Methods: OA patients were treated with CS (800 mg/day) or paracetamol
(4 g/day) for 6 month. Clinical examinationwas performed at baseline, and
after 1.5, 6 and 9 months of treatment, with collection of plasma and
synovial ﬂuid. The clinical examination included measurement of the
overﬂow, hypertrophy and vascularisation of the synovia as well as func-
tional study of the articulation (with Lequesne and EVA index). The levels
of CXCL16, fractalkine/CX3CL1, MCP-1/CCL-2, RANTES/CCL5 and GRO-a/
CXCL1 were determined by ELISA in the plasma and synovial samples
collected. The statistical analysis was performed with SPSS package. We
performed two different analyses. In the ﬁrst one, we studied the differ-
ence between the levels of the chemokine between each time and the
baseline. We performed this analysis in separate with the paracetamol
group and chondroitin one. For this comparison we used a non parametric
test (Wilcoxon 2 related samples test). We performed a second analysis in
order to analyze if there were differences in the chemokine levels over
time, depending on the treatment received. For this analysis an indepen-
dent sample t-test was performed.
Results: Improvements in the clinical signs of inﬂammationwere detected
after 6-9 months after CS treatment of OA patients. The comparison of the
levels of each chemokine at the different times studied versus the baseline,
indicated us that these effects were accompanied by a signiﬁcant reduction
in the synovial levels of MCP-1 at 6 month (p¼0.05), whereas in the par-
acetamol group there was a signiﬁcant increased level of RANTES
(p¼0.035). In plasma, only MCP-1 concentration was signiﬁcant dimin-
ished (p¼0.023) by CS administration. To study in global the answer to the
treatments, we perform a comparison between the effect of each drug to
the levels of each chemokine. This analysis showed us that there were
signiﬁcant differences between the response to the treatment in MCP-1, 6
month after treatment (p¼0.016), and in fractalkine, 9 month after treat-
ment (p¼0.036). In both cases the treatment with chondroitin showed
a diminution of the levels of the chemokines, while paracetamol didn't
affect in the case of MCP-1 or even increased in the case of fractalkine. All
these data show that chemokine attraction of macrophage, T-cell, eosin-
ophil and basophil is reduced with a 6 month treatment with chondroitin.
Conclusions: These results suggest that CS sulphate may represent an
adequate drug to reduce the inﬂammation associated to the OA process.
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LINKING AN ADAMTS5-SPECIFIC THERAPEUTIC MONOCLONAL
ANTIBODY TO A SENSITIVE BIOCHEMICAL MARKER OF TARGET
ENGAGEMENT AND ACTIVITY FOR POTENTIAL APPLICATION AS
A COMPANION DIAGNOSTIC
J. Larkin. GlaxoSmithKline, King of Prussia, PA, USA
Purpose: The goal of co-developing a companion diagnostic alongside
a therapeutic has distinct advantages for drug development and has
recently been suggested by some regulatory agencies to be the preferred
scenario for future approvals. The ability to identify patient subsets most
likely to respond to and beneﬁt from a treatment not only allows for
focused stratiﬁcation and reduced development costs, but also has the
potential to reduce healthcare expenditures through deﬁned treat/non-
treat guidelines. This scenario is especially useful in the context of osteo-
arthritis (OA) where the sheer patient numbers, multifactorial etiology and
unmet need of the patient population dictates an effective stratiﬁed
approach to clinical development and market acceptance.
Methods: The Target: ADAMTS5 - A Disintegrin And Metalloprotease with
ThromboSpondin motifs 5, is a key protease involved in degradation of
cartilage (aggrecan). Activity is upregulated in osteoarthritis1,2 and
inﬂammatory arthritic1,3 diseases leading to impaired joint function and
disability. Genetic loss of function is associated with cartilage protection in
preclinical disease models4-6.
The Therapeutic: A high afﬁnity humanized mAb that speciﬁcally binds
and neutralizes ADAMTS5, engages the target in vivo (cartilage), inhibits
cartilage degradation with extended duration in human OA cartilage
explant studies, and dose dependently modulates circulating ARGS neo-
epitope levels following systemic administration in cynomolgus monkeys,
supporting its potential as an OA disease modifying drug.
Results: The Diagnostic: ARGS Neoepitope - A sensitive immunoassay
capable of quantifying a speciﬁc ‘signature’ of ADAMTS5-mediated
cleavage of aggrecan in serum, plasma, urine and synovial ﬂuid withapplications for patient selection, monitoring response and potentially
efﬁcacy.
Conclusions: The Therapeutic Proﬁle: By delaying structural disease
progression, and stabilizing or improving pain and/or function, it will ﬁll
a large unmet need in joint diseases. As a chronic therapy, the safety proﬁle
will be suitable for long term administration.
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THE ESSENTIAL OIL OF ERYNGIUM DURIAEI SUBSP. JURESIANUM
INHIBITS IL-1b INDUCED NF-KB AND MAPK ACTIVATION IN HUMAN
CHONDROCYTES
A.T. Ruﬁno 1,2, C. Cavaleiro 3, F. Judas 4, L. Salgueiro 3, M.C. Lopes 1,2,
A.F. Mendes 1,2. 1Ctr. for NeuroSci. and Cell Biology, Coimbra, Portugal;
2 Faculty of Pharmacy, Univ. of Coimbra, Coimbra, Portugal; 3 Lab. of
Pharmacognosy, Faculty of Pharmacy/CEF, Univ. of Coimbra, Coimbra, Portugal;
4Univ. Hosp. of Coimbra and Faculty ofMed., Univ. of Coimbra, Coimbra, Portugal
Purpose: Intracellular signaling pathways, including NF-kB and mitogen-
activated protein kinases (MAPK), modulated by pro-inﬂammatory cyto-
kines, like IL-1b, are known to regulate several genes involved in the
inﬂammatory and catabolic processes that lead to cartilage degradation.
Therefore, these signaling intermediates are considered promising targets
for the development of anti-osteoarthritic drugs with potential disease
modifying properties. Essential oils are complexmixtures of lowmolecular
weight lipophilic molecules with favorable pharmacokinetic properties
that make them especially suited collections for drug screening. Our
previous studies showed that the essential oil isolated from the aerial parts
of Eryngium duriaei subsp. juresianum (M. Laínz) M. Laínz (an Apiaceae
species endemic in the Iberian Peninsula) reduced IL-1b-induced iNOS
expression and nitric oxide production. This work aimed at further eluci-
dating the mechanism of action of that essential oil in human chon-
drocytes, as part of a strategy to identify natural compounds with potential
disease modifying anti-osteoarthritic activity.
Methods: Knee cartilage samples (n¼5) were obtained from multi-organ
donors (23 to 67 years old, mean¼43.2) at the University Hospital of
Coimbrawith approval by the Ethics Committee. After enzymatic digestion,
cells were plated and cultured under non-proliferating conditions. C28/I2
chondrocytic cells were used in some experiments. Cells were serum
starved for 8 to 24 h and treatedwith 3 different concentrations of essential
oil solutions inDMSO for 30minbefore stimulationwith IL-1b,10ng/mL, for
5 or 30 min. The protein levels of total and phosphorylated IkBa, and
phosphorylated p38, JNK and ERK1/2MAPKwere assessed bywestern blot.
Results: In a concentration of 0.02% (v/v), the essential oil signiﬁcantly
decreased IL-1-induced phosphorylation of IkBa, JNK, p38 and ERK1/2 by
78.03.9%, 55.66.7%, 36.40.6% and 24.43.3%, respectively (p<0.001).
Even in a concentration nearly 10 fold lower (0.0025% v/v), the essential oil
still inhibited JNK and p38 phosphorylation by 21.94.48% and 23.16.11%,
respectively (p<0.05).
Conclusions: These results show that the essential oil of E. duriaei subsp.
juresianum reduces both IL-1-induced NF-kB and MAPK activation,
although it is more effective towards inhibition of NF-kB and JNK. Taken
together, the results obtained suggest that this essential oil contains
compound(s) that may present anti-inﬂammatory and anti-catabolic
properties, and thus, potential disease-modifying anti-osteoarthritic
activity. Future work will focus on the fractionation and identiﬁcation of
those compounds followed by further pharmacologic characterization.
Therapy – Surgical & Intraarticular
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10 YEAR SURVIVORSHIP OF THE MEDIAL OXFORD
UNICOMPARTMENTAL KNEE ARTHROPLASTY. A 1000 PATIENT NON-
DESIGNER SERIES - THE EFFECT OF SURGICAL GRADE AND SUPERVISON.
L. Jones, N. Bottomley, H. Pandit, D. Beard, W. Jackson, A. Price. Nufﬁeld
Dept. of Orthopaedics, Rheumatology and Musculoskeletal Sci., Oxford,
United Kingdom
Purpose: The Oxford Unicompartmental Knee Arthroplasty (OUKA) is
a well established treatment option for anteromedial gonarthrosis. The
